

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
14 December 2023 (14.12.2023)



(10) International Publication Number
WO 2023/240109 A1

(51) International Patent Classification:

A61K 38/03 (2006.01) A61P 31/12 (2006.01)
A61K 38/17 (2006.01) C07K 16/28 (2006.01)

LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/US2023/068030

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

(22) International Filing Date:

07 June 2023 (07.06.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/349,770 07 June 2022 (07.06.2022) US

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(71) Applicant: **REGENERON PHARMACEUTICALS, INC.** [US/US]; 777 Old Saw Mill River Road, Tarrytown, NY 10591-6707 (US).

(72) Inventors: **KYRATSOS, Christos**; C/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY 10591-6707 (US). **EDELMAN, Kurt**; C/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY 10591-6707 (US).

(74) Agent: **CHEN, Hongfan** et al.; Troutman Pepper Hamilton Sanders LLP, 875 Third Avenue, New York, NY 10022 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,

(54) Title: MULTISPECIFIC MOLECULES FOR MODULATING T-CELL ACTIVITY, AND USES THEREOF

(57) Abstract: The invention provides multispecific molecules that are capable of binding to an antigen-specific T cell receptor (TCR) expressed on a surface of a cell, said multispecific molecules comprising a first molecule and a second molecule, wherein the first molecule is a polypeptide comprising (i) a peptide (p) presented in the context of a major histocompatibility complex (MHC) molecule (pMHC complex), and (ii) a first multimerization domain, and the second molecule is a polypeptide comprising (i) a domain that specifically binds a molecule expressed on the surface of the cell expressing the TCR, and (ii) a second multimerization domain, and the use of such molecules for modulating T cell activity and treating diseases such as cancers, infections, and autoimmune disorders.



WO 2023/240109 A1